Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib

BACKGROUND: Metastatic breast cancers (MBC) with no expression of human epidermal growth factor receptor-2 (HER2) are recently classified into two groups; HER2-zero [HER2-immunohistochemistry (IHC) score of 0 (IHC-0)] and HER2-low, defined as those with IHC score of 1+ or 2+ with negative in situ hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharaf, Baha’, Abu-Fares, Hala, Tamimi, Faris, Al-Sawajneh, Suhaib, Salama, Osama, Daoud, Rand, Alhajahjeh, Abdulrahman, Al-Lababidi, Sawsan, Abdel-Razeq, Hikmat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392820/
https://www.ncbi.nlm.nih.gov/pubmed/37533590
http://dx.doi.org/10.2147/BCTT.S415432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392820/
https://www.ncbi.nlm.nih.gov/pubmed/37533590
http://dx.doi.org/10.2147/BCTT.S415432

Ejemplares similares